Last $130.10 USD
Change Today +1.56 / 1.21%
Volume 14.4K
BAYRY On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
BrsaItaliana
Xetra
Mexico
Continuous
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-sponsored adr (BAYRY) Snapshot

Open
$129.61
Previous Close
$128.54
Day High
$130.35
Day Low
$129.24
52 Week High
12/30/13 - $142.75
52 Week Low
04/22/13 - $101.00
Market Cap
107.6B
Average Volume 10 Days
46.5K
EPS TTM
--
Shares Outstanding
826.9M
EX-Date
04/25/14
P/E TM
--
Dividend
$2.89
Dividend Yield
1.90%
Current Stock Chart for BAYER AG-SPONSORED ADR (BAYRY)

bayer ag-sponsored adr (BAYRY) Related Bloomberg News

View More Bloomberg News

bayer ag-sponsored adr (BAYRY) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as contraceptives, hemophilia treatments, anticoagulants, and medicines to treat multiple sclerosis, cancer, hypertension, and infectious diseases; and consumer health products comprising over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; contrast agent injection systems for diagnostic and therapeutic medical procedures in computed tomography, magnetic resonance imaging, and molecular imaging; and mechanical systems for removing thrombi from blood vessels, as well as service products for its systems. The CropScience segment offers products for use in agriculture as insecticides, fungicides, and herbicides or seed treatments; seeds and plant traits; and various products for gardens, green industry, and nonagricultural pest control. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and functional films; and produces and markets inorganic basic chemicals. The company has a strategic alliance with OncoMed Pharmaceuticals, Inc. to develop drugs to target cancer stem cell therapeutics. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

107,700 Employees
Last Reported Date: 02/28/14
Founded in 1863

bayer ag-sponsored adr (BAYRY) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €2.9M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €1.8M
Labor Director and Member of Management Board
Total Annual Compensation: €1.1M
Member of Management Board
Total Annual Compensation: €2.2M
Compensation as of Fiscal Year 2013.

bayer ag-sponsored adr (BAYRY) Key Developments

Bayer Launches Phase III Trial for Xofigo in Combination with Janssen's Zytiga

Bayer has launched a Phase III trial investigating its already marketing approved drug Xofigo (radium-223) in combination with Zytiga (abiraterone acetate; Janssen, part of Johnson and Johnson, J&J, US) and prednisone/prednisolone in asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer (CRPC). The Phase III trial, which is designed as a randomised, double-blind, placebo-controlled study, enrolled about 800 patients who will be treated until an on-study symptomatic skeletal event (SSE) occurs or other withdrawal criteria are met. Although it has been announced that Bayer will sponsor the trial, it will be undertaken in Janssen's research and development (R&D) facilities in a number of regions, such as Europe, Australia, and Japan. Xofigo gained market authorisation approval by the European Commission in November 2013 for the treatment of adults with CRPC, symptomatic bone metastases, and no known visceral metastases. Meanwhile, over two years prior to this, Janssen gained European Union-wide marketing approval for its prostatic neoplasms product Zytiga, in September 2011. The latter of the two is already used in as many as 80 markets and is indicated in combination with prednisone/prednisolone for the treatment of metastatic CRPC in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated or whose disease has progressed on or after a docetaxel-based chemotherapy regimen. Xofigo has been moderately received by payors in some preliminary assessments across Europe, whereby the German Institute for Quality and Efficiency in Healthcare (IQWiG) in April issued a statement claiming to have found a "hint" of a major additional benefit. Meanwhile, a few weeks earlier, the United Kingdoms' National Institute for Health and Care Excellence (NICE) did not recommend the product for use within the National Health Service in England and Wales in its draft guidance.

Sanofi Reportedly To Acquire Merck's Consumer Unit

Sanofi (ENXTPA:SAN) is reportedly looking to acquire Merck & Co. Inc. (NYSE:MRK) over-the-counter health products unit, people with knowledge of the matter said. Final bids are due next week, two people said, asking not to be identified discussing private information. Reckitt Benckiser Group plc (LSE:RB.) is the most aggressive bidder making it the frontrunner for the business, three people said. Novartis AG (SWX:NOVN) has discussed swapping its animal-health business with Merck’s consumer-health unit, people with knowledge of the matter said in January 2014. Bayer AG (DB:BAYN) is also interested in Merck’s consumer business, three people said. According to Bloomberg, Spokesmen for Sanofi, Reckitt Benckiser, Bayer, Merck and Novartis declined to comment. Sanofi shares rose 1.7%.

Bayer to Invest EUR 500 Million at German Sites

Bayer is investing more than EUR 500 million at its sites in Wuppertal and Leverkusen, Germany. The company is investing to expand manufacturing capacities for recombinant factor VIII (rFVIII) haemophilia products that are presently in development. It is producing the approved haemophilia A therapy drug Kogenate FS/Kogenate Bayer at its Berkeley facility in California. Setting up an additional supply source in Germany will help the company to prepare for production of the anticipated new therapy options and address the increasing demand in this therapeutic area. The firm is creating around 500 new jobs by 2020 as part of this investment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYRY:US $130.10 USD +1.56

BAYRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,559 GBp -4.50
Sanofi €75.48 EUR +0.71
Saudi Basic Industries Corp SR113.63 SAR +0.16
Dow Chemical Co/The $48.72 USD +0.22
Unilever NV €30.54 EUR -0.16
View Industry Companies
 

Industry Analysis

BAYRY

Industry Average

Valuation BAYRY Industry Range
Price/Earnings 24.2x
Price/Sales 1.9x
Price/Book 3.7x
Price/Cash Flow 24.2x
TEV/Sales 1.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-SPONSORED ADR, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.